Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee; Amendment of Notice, 17417 [2010-7697]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 65 / Tuesday, April 6, 2010 / Notices
17417
Dated: April 1, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Food and Drug Administration
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
[Docket No. FDA–2010–N–0001]
BILLING CODE 4160–01–S
Joint Meeting of the Arthritis Advisory
Committee and the Drug Safety and
Risk Management Advisory
Committee; Amendment of Notice
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Clinical Trial
Review Meeting.
Date: May 3, 2010.
Time: 3:30 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: John F. Connaughton, PhD,
Chief, Chartered Committees Section, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 753, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7797,
connaughtonj@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: March 31, 2010.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–7746 Filed 4–5–10; 8:45 am]
sroberts on DSKD5P82C1PROD with NOTICES
BILLING CODE 4140–01–P
VerDate Nov<24>2008
16:37 Apr 05, 2010
Jkt 220001
[FR Doc. 2010–7697 Filed 4–5–10; 8:45 am]
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
amendment to the notice of a joint
meeting of the Arthritis Advisory
Committee and the Drug Safety and Risk
Management Advisory Committee. This
meeting was announced in the Federal
Register of March 8, 2010 (75 FR
10490). The amendment is being made
to reflect a change in the Agenda
portion of the document. There are no
other changes.
FOR FURTHER INFORMATION CONTACT:
Anuja Patel, Center for Drug Evaluation
and Research (HFD–21), Food and Drug
Administration, 5600 Fishers Lane (for
express delivery, 5630 Fishers Lane, rm.
1093), Rockville, MD 20857, 301–827–
7001, FAX: 301–827–6776, e-mail:
Anuja.Patel@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington DC area), codes 3014512532
and 3014512535. Please call the
Information Line for up-to-date
information on this meeting.
In the
Federal Register of March 8, 2010, FDA
announced that a joint meeting of the
Arthritis Advisory Committee and the
Drug Safety and Risk Management
Advisory Committee would be held on
May 12, 2010. On page 10490, in the
second column, the Agenda portion of
the document is changed to read as
follows:
Agenda: The committees will discuss
new drug application (NDA) 22–478,
naproxcinod 375 milligram capsule,
sponsored by NicOx S.A. Naproxcinod
is a non-steroidal anti-inflammatory
drug (NSAID) product indicated for the
treatment of the signs and symptoms of
osteoarthritis.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to the advisory committees.
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
Food and Drug Administration
[Docket No. FDA–2010–N–0001]
Peripheral and Central Nervous
System Drugs Advisory Committee;
Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Peripheral and
Central Nervous System Drugs Advisory
Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on June 10, 2010, from 8 a.m. to 5
p.m.
Location: Hilton Washington DC/
Silver Spring, The Ballrooms, 8727
Colesville Rd., Silver Spring, MD. The
hotel telephone number is 301–589–
5200.
Contact Person: Diem-Kieu Ngo,
Center for Drug Evaluation and Research
(HFD–21), Food and Drug
Administration, 5600 Fishers Lane (for
express delivery, 5630 Fishers Lane, rm.
1093, Rockville, MD 20857, 301–827–
7001, FAX: 301–827–6776, e-mail:
diem.ngo@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
3014512543. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: On June 10, 2010, the
committee will discuss new drug
application (NDA) 22–527, with the
E:\FR\FM\06APN1.SGM
06APN1
]]>Agencies
[Federal Register Volume 75, Number 65 (Tuesday, April 6, 2010)]
[Notices]
[Page 17417]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-7697]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0001]
Joint Meeting of the Arthritis Advisory Committee and the Drug
Safety and Risk Management Advisory Committee; Amendment of Notice
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
amendment to the notice of a joint meeting of the Arthritis Advisory
Committee and the Drug Safety and Risk Management Advisory Committee.
This meeting was announced in the Federal Register of March 8, 2010 (75
FR 10490). The amendment is being made to reflect a change in the
Agenda portion of the document. There are no other changes.
FOR FURTHER INFORMATION CONTACT: Anuja Patel, Center for Drug
Evaluation and Research (HFD-21), Food and Drug Administration, 5600
Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093),
Rockville, MD 20857, 301-827-7001, FAX: 301-827-6776, e-mail:
Anuja.Patel@fda.hhs.gov, or FDA Advisory Committee Information Line, 1-
800-741-8138 (301-443-0572 in the Washington DC area), codes 3014512532
and 3014512535. Please call the Information Line for up-to-date
information on this meeting.
SUPPLEMENTARY INFORMATION: In the Federal Register of March 8, 2010,
FDA announced that a joint meeting of the Arthritis Advisory Committee
and the Drug Safety and Risk Management Advisory Committee would be
held on May 12, 2010. On page 10490, in the second column, the Agenda
portion of the document is changed to read as follows:
Agenda: The committees will discuss new drug application (NDA) 22-
478, naproxcinod 375 milligram capsule, sponsored by NicOx S.A.
Naproxcinod is a non-steroidal anti-inflammatory drug (NSAID) product
indicated for the treatment of the signs and symptoms of
osteoarthritis.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.
Dated: April 1, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2010-7697 Filed 4-5-10; 8:45 am]
BILLING CODE 4160-01-S
